Publication:
The efficacy and drug survival of the biosimilar infliximab (ct-p13) compared to the original reference infliximab in inflammatory rheumatic diseases; Results from the turkbio registry

dc.contributor.authorUslu, Sadettin
dc.contributor.authorCan, Gerçek
dc.contributor.authorŞenel, Soner
dc.contributor.authorİnanç, Nevsun
dc.contributor.authorAkars, Servet
dc.contributor.authorKocaer, Sinem Burcu
dc.contributor.authorBirlik, Merih
dc.contributor.authorCapar, Sedat
dc.contributor.authorAkkoç, Nurullah
dc.contributor.authorÖnen, Fatoş
dc.contributor.buuauthorDalkılıç, Ediz
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentRomatoloji Bilim Dalı
dc.date.accessioned2024-01-08T10:09:21Z
dc.date.available2024-01-08T10:09:21Z
dc.date.issued2018-09
dc.identifier.citationUslu, S. vd. (2018). ''The efficacy and drug survival of the biosimilar infliximab (ct-p13) compared to the original reference infliximab in inflammatory rheumatic diseases; Results from the turkbio registry''. Arthritis & Rheumatology, 70(Supplement 9).
dc.identifier.issn2326-5191
dc.identifier.issn2326-5205
dc.identifier.issueSupplement 9
dc.identifier.urihttps://hdl.handle.net/11452/38832
dc.identifier.volume70
dc.identifier.wos000447268904265
dc.language.isoen
dc.publisherWiley
dc.relation.collaborationYurt içi
dc.relation.journalArthritis & Rheumatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectRheumatology
dc.subject.wosRheumatology
dc.titleThe efficacy and drug survival of the biosimilar infliximab (ct-p13) compared to the original reference infliximab in inflammatory rheumatic diseases; Results from the turkbio registry
dc.typeArticle
dc.wos.quartileQ1 (Rheumatology)
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Romatoloji Bilim Dalı
local.indexed.atPubMed

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: